|

PD-1 / PD-L1 monoclonal antibody Clinical Trials

3 actively recruiting trials across 1 location

Also known as: PD -1/PD-L1antibody, Radiotherapy.

Pipeline

Early 1: 1Phase 1/2: 1

Top Sponsors

  • Second Affiliated Hospital, School of Medicine, Zhejiang University1
  • Repertoire Immune Medicines1
  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • Cancer3
  • Advanced Lung Cancer1
  • Advanced Malignant Solid Tumor1
  • Advanced Breast Cancer1
  • Lung Cancer1

Other2 trials

A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
Early 1

Grand Rapids, Michigan1 trial

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

START Midwest

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.